Catalyst Pharmaceuticals Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Catalyst Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,370,000 shares, an increase of 29.5% from the March 15th total of 9,550,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is presently 7.0 days. Currently, 12.8% of the shares of the stock are short sold.
View Catalyst Pharmaceuticals' Short Interest.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Tuesday, March, 16th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The biopharmaceutical company earned $31.02 million during the quarter, compared to analyst estimates of $30.06 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%.
View Catalyst Pharmaceuticals' earnings history.

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 26.1% and is now trading at $4.44.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1-year price targets for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.50 to $10.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $7.63 in the next year. This suggests a possible upside of 71.7% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Catalyst Pharmaceuticals include FibroGen (FGEN), Morphic (MORF), Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), Heron Therapeutics (HRTX), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), Generation Bio (GBIO), Aurinia Pharmaceuticals (AUPH) and uniQure (QURE).
View all of CPRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Prairiewood Capital LLC (0.25%) and Wedge Capital Management L L P NC (0.03%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC.
View insider buying and selling activity for Catalyst Pharmaceuticals or view top insider-selling stocks.

CPRX stock was bought by a variety of institutional investors in the last quarter, including Prairiewood Capital LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals or or view top insider-buying stocks.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $4.44.

Catalyst Pharmaceuticals has a market capitalization of $460.98 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis.

Catalyst Pharmaceuticals employs 76 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]